Abstract
In a phase III clinical trial, previously untreated patients with acute myeloid leukemia and FLT3 mutations received either the FLT3 inhibitor midostaurin or a placebo during chemotherapy. Patients who received midostaurin had a 5-year survival rate of 50.9% compared with 43.9% for the placebo group, as well as remissions that lasted nearly a year longer.
©2016 American Association for Cancer Research.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Congresses as Topic
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / mortality*
-
Middle Aged
-
Mutation
-
Staurosporine / analogs & derivatives*
-
Staurosporine / therapeutic use
-
Survival Analysis
-
Treatment Outcome
-
fms-Like Tyrosine Kinase 3 / genetics
Substances
-
Antineoplastic Agents
-
FLT3 protein, human
-
fms-Like Tyrosine Kinase 3
-
Staurosporine
-
midostaurin